PharmaCielo Ltd.
PCLOF
$0.0478
-$0.0067-12.29%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 271.59% | 382.07% | -69.36% | -83.91% | -28.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 271.59% | 382.07% | -69.36% | -83.91% | -28.03% |
| Cost of Revenue | 34.32% | -35.02% | -34.60% | -63.04% | -12.73% |
| Gross Profit | 204.73% | 144.28% | -106.71% | -180.51% | -11.05% |
| SG&A Expenses | -36.23% | -19.28% | -55.46% | -46.50% | -39.09% |
| Depreciation & Amortization | -42.41% | -54.60% | 5.78% | 107.81% | -79.01% |
| Other Operating Expenses | 9.25% | 8.05% | 87.92% | -- | -- |
| Total Operating Expenses | -18.12% | -24.39% | -48.59% | -36.78% | -38.68% |
| Operating Income | 62.57% | 45.93% | 43.28% | -15.44% | 40.04% |
| Income Before Tax | 5.83% | 29.47% | 31.79% | -118.84% | 48.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.83% | 29.47% | 31.79% | -118.84% | 48.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.83% | 29.47% | 31.79% | -118.84% | 48.13% |
| EBIT | 62.57% | 45.93% | 43.28% | -15.44% | 40.04% |
| EBITDA | 57.59% | 40.44% | 39.81% | -16.54% | 45.32% |
| EPS Basic | 5.51% | 34.71% | 37.65% | -100.71% | 51.53% |
| Normalized Basic EPS | 34.18% | 34.91% | 36.45% | -41.30% | 51.53% |
| EPS Diluted | 5.51% | 34.71% | 37.65% | -100.71% | 51.53% |
| Normalized Diluted EPS | 34.18% | 34.91% | 36.45% | -41.30% | 51.53% |
| Average Basic Shares Outstanding | 0.00% | 8.22% | 9.14% | 9.01% | 7.16% |
| Average Diluted Shares Outstanding | 0.00% | 8.22% | 9.14% | 9.01% | 7.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
